ANAB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options. In 27 of 30 cases where ANAB's price broke its lower Bollinger Band, its price rose further in the following month. The odds of a continued upward trend are 90%.
The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ANAB's RSI Oscillator exited the oversold zone, 17 of 21 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 81%.
The Stochastic Oscillator suggests the stock price trend may be in a reversal from a downward trend to an upward trend. 50 of 60 cases where ANAB's Stochastic Oscillator exited the oversold zone resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 83%.
The Momentum Indicator moved above the 0 level on October 15, 2026. You may want to consider a long position or call options on ANAB as a result. In 79 of 94 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 84%.
The Moving Average Convergence Divergence (MACD) for ANAB just turned positive on October 15, 2026. Looking at past instances where ANAB's MACD turned positive, the stock continued to rise in 44 of 53 cases over the following month. The odds of a continued upward trend are 83%.
Following a +6.84% 3-day Advance, the price is estimated to grow further. Considering data from situations where ANAB advanced for three days, in 226 of 285 cases, the price rose further within the following month. The odds of a continued upward trend are 79%.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where ANAB declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 81%.
The Aroon Indicator for ANAB entered a downward trend on October 15, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.
The Tickeron Profit vs. Risk Rating rating for this company is 37 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Price Growth Rating for this company is 43 (best 1 - 100 worst), indicating steady price growth. ANAB’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 61 (best 1 - 100 worst), pointing to consistent earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 96 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (142.857) is normal, around the industry mean (26.782). P/E Ratio (97.087) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (6.614) is also within normal values, averaging (437.542).
The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
PBYI saw its Momentum Indicator move above the 0 level on October 07, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 96 similar instances where the indicator turned positive. In 89 of the 96 cases, the stock moved higher in the following days. The odds of a move higher are at 90%.
The Moving Average Convergence Divergence (MACD) for PBYI just turned positive on October 09, 2026. Looking at past instances where PBYI's MACD turned positive, the stock continued to rise in 40 of 45 cases over the following month. The odds of a continued upward trend are 89%.
Following a +3.95% 3-day Advance, the price is estimated to grow further. Considering data from situations where PBYI advanced for three days, in 259 of 291 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
The Aroon Indicator entered an Uptrend today. In 199 of 227 cases where PBYI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 88%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 4 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PBYI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 80%.
PBYI broke above its upper Bollinger Band on October 09, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron PE Growth Rating for this company is 4 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. PBYI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron Seasonality Score of 36 (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 61 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of 74 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.659) is normal, around the industry mean (26.782). P/E Ratio (19.275) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (2.105) is also within normal values, averaging (437.542).
ANAB | PBYI | ||
|---|---|---|---|
OUTLOOK RATING 1..100 | 57 | 41 | |
VALUATION overvalued / fair valued / undervalued 1..100 | 96 Overvalued | 74 Overvalued | |
PROFIT vs RISK RATING 1..100 | 37 | 61 | |
SMR RATING 1..100 | 99 | 44 | |
PRICE GROWTH RATING 1..100 | 43 | 36 | |
P/E GROWTH RATING 1..100 | 61 | 4 | |
SEASONALITY SCORE 1..100 | 75 | 36 |
Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.
PBYI's Valuation (74) in the Biotechnology industry is in the same range as ANAB (96). This means that PBYI’s stock grew similarly to ANAB’s over the last 12 months.
ANAB's Profit vs Risk Rating (37) in the Biotechnology industry is in the same range as PBYI (61). This means that ANAB’s stock grew similarly to PBYI’s over the last 12 months.
PBYI's SMR Rating (44) in the Biotechnology industry is somewhat better than the same rating for ANAB (99). This means that PBYI’s stock grew somewhat faster than ANAB’s over the last 12 months.
PBYI's Price Growth Rating (36) in the Biotechnology industry is in the same range as ANAB (43). This means that PBYI’s stock grew similarly to ANAB’s over the last 12 months.
PBYI's P/E Growth Rating (4) in the Biotechnology industry is somewhat better than the same rating for ANAB (61). This means that PBYI’s stock grew somewhat faster than ANAB’s over the last 12 months.
| ANAB | PBYI | |
|---|---|---|
| RSI ODDS (%) | 2 days ago 81% | N/A |
| Stochastic ODDS (%) | 2 days ago 83% | 2 days ago 72% |
| Momentum ODDS (%) | 2 days ago 84% | 2 days ago 90% |
| MACD ODDS (%) | 2 days ago 83% | 2 days ago 89% |
| TrendWeek ODDS (%) | 2 days ago 82% | 2 days ago 87% |
| TrendMonth ODDS (%) | 2 days ago 81% | 2 days ago 87% |
| Advances ODDS (%) | 2 days ago 79% | 2 days ago 89% |
| Declines ODDS (%) | 10 days ago 81% | 15 days ago 80% |
| BollingerBands ODDS (%) | 2 days ago 90% | 2 days ago 78% |
| Aroon ODDS (%) | 2 days ago 81% | 2 days ago 88% |
It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).
ANAB’s FA Score shows that 0 FA rating(s) are green while PBYI’s FA Score has 1 green FA rating(s).
It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.
If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.
ANAB’s TA Score shows that 6 TA indicator(s) are bullish while PBYI’s TA Score has 4 bullish TA indicator(s).
ANAB (@Biotechnology) experienced а +5.41% price change this week, while PBYI (@Biotechnology) price change was +5.52% for the same time period.
The average weekly price growth across all stocks in the @Biotechnology industry was -10.70%. For the same industry, the average monthly price growth was -18.24%, and the average quarterly price growth was -21.46%.
ANAB is expected to report earnings on Nov 04, 2026.
PBYI is expected to report earnings on Oct 29, 2026.
Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.